6955 — Shandong Boan Biotechnology Share News
0.000.00%
Last trade - 00:00- HK$1.96bn
- HK$1.66bn
- CNY784.82m
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil
Brief: Shandong Boan Biotechnology Says CDE Approves Phase II Trial Of Anti-CD25 Antibody With PD-1 Inhibitor For NSCLC
Brief: Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US
Brief: Shandong Boan Biotechnology Says BLA Submission For Two Denosumab Biosimilars In U.S.
Brief: Shandong Boan Biotechnology Says Boluojia (Denosumab Injection) Approved By NMPA
Brief: Shandong Boan Biotechnology To Repurchase Shares Up To Hk$200 Million
Brief: Shandong Boan Biotechnology Says Dou Changlin Resigned As Executive Director
Brief: Shandong Boan Biotechnology Will Lease Assets At Purchase Price Of RMB41.1 Million
Brief: Shandong Boan Biotechnology Says Boyoujing Approved For Marketing In China By NMPA
Luye slides to near 6-month low on plan to issue $150 mln exchangeable shares for Boan unit
Brief: Shandong Boan Biotechnology Says Marketing Authorisation Applications For Two Denosumab Injections Accepted In UK
Brief: Shandong Boan Biotechnology Says Dulaglutide Injection Approved For Marketing By Nmpa
Brief: Shandong Boan Biotechnology To Place 48 MLN Shares At HK$16.42 Per Share
Brief: Shandong Boan Biotechnology Obtains Approval For Initiating Clinical Trials For BA1302 In U.S
Brief: Shandong Boan Biotechnology Appoints Wang Shenghan As Executive Director
HK-listed Shandong Boan falls on discounted share sale